FGFR3 and achondroplasia: VOXZOGOTM (vosoritide) injection received initial United States FDA approval in November of 2021.2 Specifically targeted to inhibit downstream signaling of FGFR3, it is intended to increase linear growth in pediatric patients with achondroplasia 5 years of age and older with open epiphyses, indicating growth potential (see text footnote 2).